The Retatrutide Gold Rush: How America Started Selling a Drug That Isn’t Even on the Market Yet
The Retatrutide Gold Rush: How America Started Selling a Drug That Isn’t Even on the Market Yet Retatrutide may be one of the most anticipated weight-loss drugs in America. There is just one problem: It isn’t on the market yet. As of September 2026, retatrutide remains an investigational drug being developed by Eli Lilly. It has produced impressive Phase 3 results, but it has not been approved by the FDA or any other regulatory agency. Yet clinics, peptide companies, telehealth operators and online vendors are already selling products represented as retatrutide. I wanted to understand what that market actually looks like from the other side. What I found should make patients—and especially licensed medical professionals—ask some very basic questions. Look at the Vial For this article, I recreated the labeling from an actual product I reviewed while changing the branding so the supplier cannot be identified. The vial contained white powder and was labeled: 16 mg CLINIC...